Editas Medicine, Inc. is a genome editing company dedicated to developing potentially transformative genomic medicines with the aim to treat a broad range of serious diseases. The Company has developed a proprietary genome editing platform based on CRISPR/Cas9 technology that address a wide variety of genetic targets. The Company’s lead program (EDIT-101) targets Leber Congenital Amaurosis 10 (LCA 10), a genetic form of retinal degeneration and blindness that is caused by mutations in the CEP290 gene. The Company’s second program (EDIT-301) aims to upregulate fetal hemoglobin by editing the beta-globin locus.